Bupropion hydrochloride (Zyban): Stock issue
GlaxoSmithKline has advised that Zyban (bupropion hydrochloride) supply is currently being managed due to increased global demand and manufacturing constraints.
Stock continues to arrive in New Zealand on a regular basis which, at the moment, is monthly. GSK is managing stock to ensure it is distributed fairly, and to minimise any disruption for those using the treatment. GSK is also aiming to increase its production volumes to cater for the new users, but due to lead times, this supply constraint may last until August 2022.
Varenicline (Champix) is unavailable due to manufacturing issue. Read the varenicline medicine notice
Nicotine patches, gum or lozenges are available and are fully funded to support people to stop smoking.
Who to contact
If you have questions about supply of Zyban, please contact GSK:
- email: email@example.com
If you have questions about funding, contact Pharmac:
- email: firstname.lastname@example.org